D.E. Shaw & Co
KRON

D.E. Shaw & Co’s Kronos Bio KRON Stock Holding History

D.E. Shaw & Co’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-254,987
Closed -$319K – 4549
2023
Q4 		$319K Sell
254,987
-115,780
-31% -$128K ﹤0.01% 3725
2023
Q3 		$482K Buy
370,767
+889
+0.2% +$1.44K ﹤0.01% 3444
2023
Q2 		$636K Buy
369,878
+53,407
+17% +$84.8K ﹤0.01% 3318
2023
Q1 		$462K Sell
316,471
-35,043
-10% -$67.2K ﹤0.01% 3590
2022
Q4 		$569K Buy
351,514
+43,167
+14% +$99.4K ﹤0.01% 3784
2022
Q3 		$1.03M Buy
308,347
+20,455
+7% +$92.3K ﹤0.01% 3575
2022
Q2 		$1.05M Buy
+287,892
New +$1.3M ﹤0.01% 3605
2021
Q1 		– Sell
-12,027
Closed -$359K – 4280
2020
Q4 		$359K Buy
+12,027
New +$377K ﹤0.01% 3536

Other funds holding KRON

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co's KRON Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Kronos Bio (KRON) in Q1 2024, closing a stake of 254,987 shares — an estimated $319K sold.

D.E. Shaw & Co first reported a position in KRON in Q4 2020 and held it in 8 quarters. The position peaked at $1.05M in Q2 2022. 58 funds tracked by Wall St. Rank hold KRON as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Kronos Bio position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 254,987 Kronos Bio shares in Q1 2024, an estimated $319K.
  • D.E. Shaw & Co first reported a position in Kronos Bio in Q4 2020 and held it in 8 quarters.
  • D.E. Shaw & Co's Kronos Bio position peaked at $1.05M in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.